항콕시듐제 시장 : 약물 클래스별(이오노포어, 합성약), 약물 작용별(Coccidiostatic, Coccidiocidal), 동물 유형별(가금류, 소, 기타) - 세계 기회 분석 및 산업 예측(2021-2031년)

The global anticoccidial drugs market was valued at $171.3 million in 2021, and is projected to reach $257.8 million by 2031, registering a CAGR of 4.2% from 2022 to 2031.

Coccidiosis is one of the most common diseases in the poultry population is caused by protozoan parasites of the genus Eimeria. These are obligated intracellular parasites with complex life cycles including sexual and asexual stages. These parasites affect the intestine making it prone to other diseases (necrotic enteritis) and reducing the ability of this organ to absorb nutrients. This disease is transmitted or spread by mechanical carriers such as insects and wild birds. However, the Eimeria eggs (oocysts) can be mechanically transported by wild birds, these parasites are host-specific and thus wild birds do not serve as a biological reservoir. Hence, this disease can be controlled by the help of anticoccidial drugs. The short life cycle of a broiler eliminates Eimeria completely from the gut by using the drugs like coccidicides that kill the parasites.

The growth of the anticoccidial drugs market is driven by the increase in development of advanced anticoccidial drugs, increase in the government initiatives for the awareness about the coccidiosis and its medications. Moreover, the high demand of animal protein food such as meat, milk, and others, increase in the outsourcing of the development of the anticoccidial drugs, and the development in the pharmaceutical and biotechnology industries also helps in the growth of the market. However, a stringent government regulations that restricts the usage of anticoccidial drugs in livestock and the use of alternative medicines such as vaccines and herbal medicines to treat coccidiosis are expected to hinder the growth of this market. Conversely, the rise in awareness about the new products available at affordable rates is expected to create lucrative opportunities for the market.

The global anticoccidial drugs market is segmented based on drug class, drug action, animal type, and region. On the basis of drug class, the market is bifurcated into ionophore and synthetic drugs. On the basis of drug action, the market is classified into coccidiostatic and coccidiocidal. On the basis of animal type, the market is classified into poultry, cattle and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key market players operating in this market include Bayer AG, Boehringer Ingelheim International GmbH, Ceva sante animale, Dosh Pharmaceuticals Private Limited, Huvepharma EOOD, Merck & Co., Inc., Venkateshwara hatcheries Private Limited, Vetoquinol SA, Virbac SA, Zoetis Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the anticoccidial drugs market analysis from 2021 to 2031 to identify the prevailing anticoccidial drugs market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the anticoccidial drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global anticoccidial drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

• Ionophore
• Synthetic Drugs

By Drug Action

• Coccidiostatic
• Coccidiocidal

By Animal Type

• Poultry
• Cattle
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
• Key Market Players
  • boehringer ingelheim animal health - us
  • Ceva sante animale
  • Huvepharma EOOD
  • Merck & Co., Inc
  • Venkateshwara hatcheries Private Limited
  • Dosh Pharmaceuticals
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc
  • Bayer AG

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Market dynamics
  • 3.4.1.Drivers
  • 3.4.2.Restraints
  • 3.4.3.Opportunities
• 3.5.COVID-19 Impact Analysis on the market

CHAPTER 4: ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Ionophore
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market share analysis by country
• 4.3 Synthetic Drugs
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market share analysis by country

CHAPTER 5: ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Coccidiostatic
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market share analysis by country
• 5.3 Coccidiocidal
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market share analysis by country

CHAPTER 6: ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Poultry
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market share analysis by country
• 6.3 Cattle
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market share analysis by country
• 6.4 Others
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market share analysis by country

CHAPTER 7: ANTICOCCIDIAL DRUGS MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Drug Class
  • 7.2.3 North America Market size and forecast, by Drug Action
  • 7.2.4 North America Market size and forecast, by Animal Type
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Key market trends, growth factors and opportunities
    • 7.2.5.1.2 Market size and forecast, by Drug Class
    • 7.2.5.1.3 Market size and forecast, by Drug Action
    • 7.2.5.1.4 Market size and forecast, by Animal Type
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Key market trends, growth factors and opportunities
    • 7.2.5.2.2 Market size and forecast, by Drug Class
    • 7.2.5.2.3 Market size and forecast, by Drug Action
    • 7.2.5.2.4 Market size and forecast, by Animal Type
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Key market trends, growth factors and opportunities
    • 7.2.5.3.2 Market size and forecast, by Drug Class
    • 7.2.5.3.3 Market size and forecast, by Drug Action
    • 7.2.5.3.4 Market size and forecast, by Animal Type
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Drug Class
  • 7.3.3 Europe Market size and forecast, by Drug Action
  • 7.3.4 Europe Market size and forecast, by Animal Type
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Key market trends, growth factors and opportunities
    • 7.3.5.1.2 Market size and forecast, by Drug Class
    • 7.3.5.1.3 Market size and forecast, by Drug Action
    • 7.3.5.1.4 Market size and forecast, by Animal Type
    • 7.3.5.2 France
    • 7.3.5.2.1 Key market trends, growth factors and opportunities
    • 7.3.5.2.2 Market size and forecast, by Drug Class
    • 7.3.5.2.3 Market size and forecast, by Drug Action
    • 7.3.5.2.4 Market size and forecast, by Animal Type
    • 7.3.5.3 UK
    • 7.3.5.3.1 Key market trends, growth factors and opportunities
    • 7.3.5.3.2 Market size and forecast, by Drug Class
    • 7.3.5.3.3 Market size and forecast, by Drug Action
    • 7.3.5.3.4 Market size and forecast, by Animal Type
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Key market trends, growth factors and opportunities
    • 7.3.5.4.2 Market size and forecast, by Drug Class
    • 7.3.5.4.3 Market size and forecast, by Drug Action
    • 7.3.5.4.4 Market size and forecast, by Animal Type
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Key market trends, growth factors and opportunities
    • 7.3.5.5.2 Market size and forecast, by Drug Class
    • 7.3.5.5.3 Market size and forecast, by Drug Action
    • 7.3.5.5.4 Market size and forecast, by Animal Type
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Key market trends, growth factors and opportunities
    • 7.3.5.6.2 Market size and forecast, by Drug Class
    • 7.3.5.6.3 Market size and forecast, by Drug Action
    • 7.3.5.6.4 Market size and forecast, by Animal Type
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
  • 7.4.3 Asia-Pacific Market size and forecast, by Drug Action
  • 7.4.4 Asia-Pacific Market size and forecast, by Animal Type
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Key market trends, growth factors and opportunities
    • 7.4.5.1.2 Market size and forecast, by Drug Class
    • 7.4.5.1.3 Market size and forecast, by Drug Action
    • 7.4.5.1.4 Market size and forecast, by Animal Type
    • 7.4.5.2 China
    • 7.4.5.2.1 Key market trends, growth factors and opportunities
    • 7.4.5.2.2 Market size and forecast, by Drug Class
    • 7.4.5.2.3 Market size and forecast, by Drug Action
    • 7.4.5.2.4 Market size and forecast, by Animal Type
    • 7.4.5.3 Australia
    • 7.4.5.3.1 Key market trends, growth factors and opportunities
    • 7.4.5.3.2 Market size and forecast, by Drug Class
    • 7.4.5.3.3 Market size and forecast, by Drug Action
    • 7.4.5.3.4 Market size and forecast, by Animal Type
    • 7.4.5.4 India
    • 7.4.5.4.1 Key market trends, growth factors and opportunities
    • 7.4.5.4.2 Market size and forecast, by Drug Class
    • 7.4.5.4.3 Market size and forecast, by Drug Action
    • 7.4.5.4.4 Market size and forecast, by Animal Type
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Key market trends, growth factors and opportunities
    • 7.4.5.5.2 Market size and forecast, by Drug Class
    • 7.4.5.5.3 Market size and forecast, by Drug Action
    • 7.4.5.5.4 Market size and forecast, by Animal Type
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Key market trends, growth factors and opportunities
    • 7.4.5.6.2 Market size and forecast, by Drug Class
    • 7.4.5.6.3 Market size and forecast, by Drug Action
    • 7.4.5.6.4 Market size and forecast, by Animal Type
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Drug Class
  • 7.5.3 LAMEA Market size and forecast, by Drug Action
  • 7.5.4 LAMEA Market size and forecast, by Animal Type
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Key market trends, growth factors and opportunities
    • 7.5.5.1.2 Market size and forecast, by Drug Class
    • 7.5.5.1.3 Market size and forecast, by Drug Action
    • 7.5.5.1.4 Market size and forecast, by Animal Type
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Key market trends, growth factors and opportunities
    • 7.5.5.2.2 Market size and forecast, by Drug Class
    • 7.5.5.2.3 Market size and forecast, by Drug Action
    • 7.5.5.2.4 Market size and forecast, by Animal Type
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Key market trends, growth factors and opportunities
    • 7.5.5.3.2 Market size and forecast, by Drug Class
    • 7.5.5.3.3 Market size and forecast, by Drug Action
    • 7.5.5.3.4 Market size and forecast, by Animal Type
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Key market trends, growth factors and opportunities
    • 7.5.5.4.2 Market size and forecast, by Drug Class
    • 7.5.5.4.3 Market size and forecast, by Drug Action
    • 7.5.5.4.4 Market size and forecast, by Animal Type

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Top player positioning, 2021
• 8.5. Competitive Dashboard
• 8.6. Competitive Heatmap
• 8.7. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 boehringer ingelheim animal health - us
  • 9.1.1 Company overview
  • 9.1.2 Key Executives
  • 9.1.3 Company snapshot
  • 9.1.4 Operating business segments
  • 9.1.5 Product portfolio
  • 9.1.6 Business performance
  • 9.1.7 Key strategic moves and developments
• 9.2 Ceva sante animale
  • 9.2.1 Company overview
  • 9.2.2 Key Executives
  • 9.2.3 Company snapshot
  • 9.2.4 Operating business segments
  • 9.2.5 Product portfolio
  • 9.2.6 Business performance
  • 9.2.7 Key strategic moves and developments
• 9.3 Huvepharma EOOD
  • 9.3.1 Company overview
  • 9.3.2 Key Executives
  • 9.3.3 Company snapshot
  • 9.3.4 Operating business segments
  • 9.3.5 Product portfolio
  • 9.3.6 Business performance
  • 9.3.7 Key strategic moves and developments
• 9.4 Merck & Co., Inc
  • 9.4.1 Company overview
  • 9.4.2 Key Executives
  • 9.4.3 Company snapshot
  • 9.4.4 Operating business segments
  • 9.4.5 Product portfolio
  • 9.4.6 Business performance
  • 9.4.7 Key strategic moves and developments
• 9.5 Venkateshwara hatcheries Private Limited
  • 9.5.1 Company overview
  • 9.5.2 Key Executives
  • 9.5.3 Company snapshot
  • 9.5.4 Operating business segments
  • 9.5.5 Product portfolio
  • 9.5.6 Business performance
  • 9.5.7 Key strategic moves and developments
• 9.6 Dosh Pharmaceuticals
  • 9.6.1 Company overview
  • 9.6.2 Key Executives
  • 9.6.3 Company snapshot
  • 9.6.4 Operating business segments
  • 9.6.5 Product portfolio
  • 9.6.6 Business performance
  • 9.6.7 Key strategic moves and developments
• 9.7 Vetoquinol SA
  • 9.7.1 Company overview
  • 9.7.2 Key Executives
  • 9.7.3 Company snapshot
  • 9.7.4 Operating business segments
  • 9.7.5 Product portfolio
  • 9.7.6 Business performance
  • 9.7.7 Key strategic moves and developments
• 9.8 Virbac SA
  • 9.8.1 Company overview
  • 9.8.2 Key Executives
  • 9.8.3 Company snapshot
  • 9.8.4 Operating business segments
  • 9.8.5 Product portfolio
  • 9.8.6 Business performance
  • 9.8.7 Key strategic moves and developments
• 9.9 Zoetis Inc
  • 9.9.1 Company overview
  • 9.9.2 Key Executives
  • 9.9.3 Company snapshot
  • 9.9.4 Operating business segments
  • 9.9.5 Product portfolio
  • 9.9.6 Business performance
  • 9.9.7 Key strategic moves and developments
• 9.10 Bayer AG
  • 9.10.1 Company overview
  • 9.10.2 Key Executives
  • 9.10.3 Company snapshot
  • 9.10.4 Operating business segments
  • 9.10.5 Product portfolio
  • 9.10.6 Business performance
  • 9.10.7 Key strategic moves and developments